Medtech grants in the United Kingdom

Closed

Funds the coordination of up to ten existing advanced-therapy research centres into one European network, with a shared roadmap for scaling up gene and cell therapy manufacturing.

Closed

Funds a pan-European network of 10-18 startup and scaleup hubs that can pass on up to EUR 60,000 per deep-tech startup for cross-border scaling support.

Closed

Funds small and medium enterprises across Europe via Eurostars Call 11 for collaborative innovation with international partners.

Closed

Funds the next development stage, TRL 5 and up, for regenerative-medicine results that already came out of an earlier, completed EU-funded research project.

Closed

Funds implementation research that tests how schools, workplaces and other non-health settings can help prevent or manage chronic disease in low- and middle-income countries and underserved communities.

Closed

Funds around two research projects, each worth EUR 1 to 2 million, to adapt EU-built generative AI to African challenges in farming, health, cities and education.

Closed

Funds consortia that build or adapt generative AI models on large-scale multimodal health data and prove their value with at least two real biomedical use cases.

Closed

Funds research teams building interactive generative-AI agents that integrate medical imaging and health data to improve cancer diagnosis and treatment.

Closed

Funds late-stage clinical trials of vaccines, monoclonal antibodies and antivirals against a named list of lower respiratory tract infection pathogens in sub-Saharan Africa.

Closed

Funds clinical trials advancing new or improved antimalarial drug combinations toward registration and access in sub-Saharan Africa.

Closed

Funds 4 regional research networks in sub-Saharan Africa to run multi-country clinical trials and rapid outbreak-response research.

Closed

Funds clinical trials of TB vaccine candidates and licensed vaccines targeting adolescents, adults and vulnerable groups in sub-Saharan Africa.

Closed

Funds late-stage clinical trials on treating co-infections and co-morbidities in people living with HIV, not HIV itself, across sub-Saharan Africa.

Closed

Funds host institutions in sub-Saharan Africa to run Master's fellowships and short courses in epidemiology, biostatistics and infectious-disease modelling, worth up to EUR 90,000 per fellow.

Closed

Funds research standardising how scientists detect and measure micro- and nanoplastics in the human body, and building evidence on their long-term health effects.

Closed

Funds five projects, €5-6M each, that develop and test care approaches built around what cancer patients over 65 actually need during and after treatment.

Closed

Funds rare-disease research calls, clinical trial networks and shared data for ERDERA's second phase — open only to the existing coordinator.

Closed

Funds research that measures wasteful or low-value healthcare practices and pilots ways to cut them, freeing up resources for care that actually helps patients.

Closed

Funds medical, technological and care research that prevents, reverses or reduces the severity of intellectual disability and supports the families who care for those affected.

Closed

Funds clinical trials of new drug-based therapies, paired with a complementary approach like neurostimulation or digital monitoring, for conditions such as depression, schizophrenia, PTSD and autism spectrum disorder.

Closed

Funds clinical trials that validate affordable, minimally-invasive surgery-centred treatments for cancer patients with locally advanced or metastatic disease.

Closed

Funds one project to standardise beta-cell manufacturing, immune-tolerance strategies and clinical criteria that speed up cell therapy for type 1 diabetes.

Closed

Funds multi-country clinical studies that generate the safety and performance data device makers need for CE marking of orphan or breakthrough medical devices.

Closed

Funds development of lab-grown human tissue models, organ-on-chip systems and AI-driven simulations that can replace animal testing in drug and medical device development.